Industry News
Biotechnology Industry News

Evaxion has scrapped a next-gen…
Evaxion has scrapped a next-gen solid tumor vaccine in order to channel resources to a candidate specifically targeting brain cancer.
Leo Pharma is sticking to its…
Leo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the FDA.
Antibody platform business OmniAb…
Antibody platform business OmniAb continues to rack up the Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.
You might assume Chinese biotechs…
You might assume Chinese biotechs are enduring sleepless nights worrying about whether the ramping up of rhetoric in the U.S. is putting their new financial gains in peril. But the companies Fierce spoke to remained
AstraZeneca has stopped a phase 3…
AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace current immune checkpoint inhibitors.
Skye Bioscience has entered into…
Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, called Fibrx Therapeutics.
Two recent patient deaths—both…
Two recent patient deaths—both involving severe immune reactions to high-dose, viral vector-delivered gene therapies and a lack of disclosures—have drawn international scrutiny to what appear to be systemic gaps in oversight and transparency within China’s
BioCryst CEO Charlie Gayer told…
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.
Capricor Therapeutics has bounced…
Capricor Therapeutics has bounced back from a bruising FDA advisory committee meeting by securing a green light to file an amendment to its approval application, raising hopes that the biotech can rescue its Duchenne muscular
Despite mixed results for its…
Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.
Just weeks after Legend Biotech…
Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed round
PDS Biotechnology has called a…
PDS Biotechnology has called a halt to its phase 3 head and neck cancer therapy to channel resources to a drug in phase 2 development for metastatic colorectal cancer.
PTC Therapeutics has struck a deal…
PTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease program for $111 million upfront, outbidding Astellas and TerSera Therapeutics for the near-approval gene therapy. Sangamo, selling assets as part of its bankruptcy
Taiho Pharmaceutical and Cullinan…
Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing the partners up to challenge Johnson & Johnson for a lung cancer niche.
As the FDA mulls whether to…
As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.
Three years after Robert Hoffman…
Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture.
Aardvark Therapeutics has…
Aardvark Therapeutics has confirmed it is walking away from recently terminated phase 3 trials, telling investors it has no plans to resume the studies “as previously designed” as it works to find a path forward
Definium Therapeutics’ LSD…
Definium Therapeutics’ LSD formula has gone two for two in its phase 3 program, notching a win in generalized anxiety disorder months after knocking a depression study out of the park.
How can industry build resilience…
How can industry build resilience as science advances? WuXi AppTec Co-CEO Dr. Steve Yang shares his perspective on the future of biopharma innovation.
Amgen is expanding its footprint…
Amgen is expanding its footprint in India with an R&D center in Hyderabad, the latest by from the California company to boost its research facilities.

